

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/695,809	ONISHI ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Brian J. Davis	1621

**All Participants:**

(1) Brian J. Davis.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_.

(2) Vincent K. Shier.

(4) \_\_\_\_\_.

**Date of Interview:** 10 February 2005

**Time:** \_\_

**Type of Interview:**

Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant     Applicant's representative)

Exhibit Shown or Demonstrated:  Yes     No

If Yes, provide a brief description:

**Part I.**

**Rejection(s) discussed:**

*possible, new 112, second paragraph, rejections of claims 13, 16 and 18*

**Claims discussed:**

*13, 16 and 18*

**Prior art documents discussed:**

*none*


**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

See Continuation Sheet

**Part III.**

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



**BRIAN DAVIS**  
**PRIMARY EXAMINER**

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: It was agreed to correct by Examiner's Amendment the structural diagram of formula (1) and to move the "halomethyl lithium" clause such that it now appears immediately before the "acid" clause. That is, that in claims 13 and 18 the "halomethyl lithium" clause becomes the penultimate clause and in claim 16 it becomes the third-to-last clause..